Hyperfine price to sales ratio HYPR

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 4.6×
4-year median: 8.2×
Against its 4-year history: 5th; percentile: 0 is its lowest day, 100 its highest
4-year range: 3.6× to 26.6×
Peer median: 1.4×

Hyperfine's price to sales ratio is 4.6× as of Oct 23, 2026.

That is below its 4-year median of 8.2×, lower than on 95% of days in the last 4 years.

Over that time it ranged from 3.6× in May 2025 to 26.6× in Jul 2023.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	4.6×	4.6×	13.5×
2025	9.7×	3.6×	12.7×
2024	4.9×	4.9×	8.8×
2023	8.2×	7.5×	26.6×
2022	10.2×	9.3×	10.8×

Against its peers

Companies in Healthcare nearest Hyperfine's size, closest first, today.

Company	Price to sales ratio
HYPRHyperfine	4.6×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	0.3×
APTAlpha Pro Tech	0.9×
ATNMActinium Pharmaceuticals	n/m
NEPHNephros	1.9×
PDEXPro DEX	2.6×
PLXProtalix BioTherapeutics	2.5×
NATRNatures Sunshine Products	0.4×
Peer median	1.4×

Where Hyperfine ranks

#18of 26Medical device stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Hyperfine

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.